Spots Global Cancer Trial Database for cutaneous t cell lymphoma
Every month we try and update this database with for cutaneous t cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma | NCT04045470 | Cutaneous T Cel... Peripheral T Ce... | Microdevices Standard of car... Standard of car... | 18 Years - | Dana-Farber Cancer Institute | |
| Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | NCT00047060 | Mycosis Fungoid... Sezary Syndrome | A matched perip... cyclosporine fludarabine Campath | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) | NCT02546440 | Cutaneous T Cel... | Dimethyl fumara... | 18 Years - | Universitätsmedizin Mannheim | |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | NCT06385522 | NHL Cutaneous T Cel... Peripheral T-ce... | BITR2101 | 18 Years - | Boston Immune Technologies and Therapeutics | |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | NCT02943642 | Mycosis Fungoid... | A-dmDT390-bisFv... Vorinostat | 18 Years - | Angimmune LLC | |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | NCT04955340 | Cutaneous T Cel... Mycosis Fungoid... Sezary Syndrome | [14C]-resminost... | 35 Years - 55 Years | 4SC AG | |
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution | NCT05728879 | Cutaneous T Cel... | APR-TD011 (RLF-... | 18 Years - | Northwestern University | |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | NCT06385522 | NHL Cutaneous T Cel... Peripheral T-ce... | BITR2101 | 18 Years - | Boston Immune Technologies and Therapeutics | |
| Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | NCT01445340 | Mycosis Fungoid... Cutaneous T-Cel... Neoplasms | Romidepsin (FR9... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | NCT05956041 | Cutaneous T Cel... Fungoides Mycos... | Pembrolizumab Mogamulizumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) | NCT02546440 | Cutaneous T Cel... | Dimethyl fumara... | 18 Years - | Universitätsmedizin Mannheim | |
| STAT3 in T Cells: At The Crossroads of Inflammation and Cancer | NCT01663571 | Cutaneous T Cel... | 18 Years - | NYU Langone Health | ||
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | NCT02576496 | Hematological M... Multiple Myelom... Hodgkin's Lymph... Cutaneous T Cel... | Tinostamustine | 18 Years - | Mundipharma Research Limited | |
| Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma | NCT01132989 | Cutaneous T Cel... | Lenalidomide | 18 Years - | Florida Academic Dermatology Centers | |
| A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) | NCT03292406 | Cutaneous T Cel... | Placebo CD11301 0.03% CD11301 0.06% | 18 Years - | Galderma R&D | |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | NCT02576496 | Hematological M... Multiple Myelom... Hodgkin's Lymph... Cutaneous T Cel... | Tinostamustine | 18 Years - | Mundipharma Research Limited | |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | NCT04955340 | Cutaneous T Cel... Mycosis Fungoid... Sezary Syndrome | [14C]-resminost... | 35 Years - 55 Years | 4SC AG | |
| Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | NCT00007345 | Cutaneous T Cel... Peripheral T Ce... | Romidepsin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma | NCT03932279 | Cutaneous T Cel... | 18 Years - 89 Years | Northwestern University | ||
| Photopheresis in Early-stage Mycosis Fungoides | NCT05680558 | Cutaneous T Cel... Mycosis Fungoid... | UVADEX® (methox... THERAKOS® CELLE... | 18 Years - | Columbia University | |
| Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light | NCT05872854 | Cutaneous T Cel... Mycosis Fungoid... | Hypericin Visible Light | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) | NCT05137847 | Lymphoma, T-cel... Lymphoma, T-cel... | Remitoro | - | Eisai Inc. | |
| Photopheresis in Early-stage Mycosis Fungoides | NCT05680558 | Cutaneous T Cel... Mycosis Fungoid... | UVADEX® (methox... THERAKOS® CELLE... | 18 Years - | Columbia University | |
| RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas | NCT01198665 | Peripheral T Ce... Anaplastic Larg... Angioimmunoblas... Cutaneous T Cel... | RAD001 (Everoli... | 20 Years - 70 Years | Samsung Medical Center | |
| Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) | NCT02546440 | Cutaneous T Cel... | Dimethyl fumara... | 18 Years - | Universitätsmedizin Mannheim | |
| Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) | NCT01676831 | Cutaneous T Cel... | Topical resiqui... topical resiqui... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | NCT05414500 | Cutaneous T Cel... Mycosis Fungoid... | Mogamulizumab Brentuximab ved... | 19 Years - | University of Alabama at Birmingham | |
| Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides | NCT05303480 | Mycosis Fungoid... | Chlormethine | 18 Years - 75 Years | Centre for Human Drug Research, Netherlands | |
| Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) | NCT02192021 | Cutaneous T Cel... | Micro needle ar... | 18 Years - | University of Pittsburgh | |
| Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma | NCT01132989 | Cutaneous T Cel... | Lenalidomide | 18 Years - | Florida Academic Dermatology Centers | |
| A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) | NCT03292406 | Cutaneous T Cel... | Placebo CD11301 0.03% CD11301 0.06% | 18 Years - | Galderma R&D | |
| Early Diagnosis of Mycosis Fungoides | NCT02539472 | Cutaneous T Cel... | Blood sampling | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | NCT01445340 | Mycosis Fungoid... Cutaneous T-Cel... Neoplasms | Romidepsin (FR9... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | NCT03775525 | Advanced Cancer Gastric Cancer Breast Cancer Pancreatic Canc... Prostate Cancer... Colo-rectal Can... Solid Tumor Solid Carcinoma Solid Carcinoma... Cancer of Stoma... Lymphoma Sarcoma Cutaneous T Cel... Head and Neck S... Basal Cell Carc... Cutaneous T-cel... Cutaneous Squam... | GZ17-6.02 Capecitabine | 18 Years - | Genzada Pharmaceuticals USA, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
